Improvement in survival of metastatic colorectal cancer: Are the benefits of clinical trials reproduced in population-based studies?
A partir des données d'un registre français des cancers portant sur 3 804 patients atteints d'un cancer colorectal métastatique non résécable diagnostiqué entre 1976 et 2009, cette étude analyse l'évolution de la survie en lien avec les progrès de la recherche clinique
To describe trends in survival of non-resectable metastatic colorectal cancer (MCRC) over a 34-year period in a French population-based registry taking into account major advances in medical therapy. 3804 patients with non-resectable metastatic colorectal cancer diagnosed between 1976 and 2009 were included. Three periods (1976–96, 1997–2004 and 2005–09) were considered. The proportion of patients receiving chemotherapy dramatically increased from 19% to 57% between the first two periods, then increased steadily thereafter reaching 59% during the last period (p<0.001). Median relative survival increased from 5.9months during the 1976–96 period to 10.2months during the 1997–2004 period but, despite the availability of targeted therapies, remained at 9.5months during the 2005–09 period. During the last study period, less than 10% of elderly patients received targeted therapies compared to more than 40% for younger patients. Their median relative survival was 5.0months compared to 15.6months in younger patients. There was an improvement in survival in relation with the increased use of more effective medical treatment. However, at a population-based level, patients are not all treated equally and most of them, especially the elderly, do not benefit from the most up-to-date treatment options.
http://linkinghub.elsevier.com/retrieve/pii/S0959804913003006?showall=true